BNP Paribas Financial Markets Sells 11,283 Shares of Nature’s Sunshine Products, Inc. (NASDAQ:NATR)

BNP Paribas Financial Markets reduced its position in shares of Nature’s Sunshine Products, Inc. (NASDAQ:NATR) by 81.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,622 shares of the company’s stock after selling 11,283 shares during the quarter. BNP Paribas Financial Markets’ holdings in Nature’s Sunshine Products were worth $36,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its holdings in shares of Nature’s Sunshine Products by 12.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 48,589 shares of the company’s stock valued at $732,000 after purchasing an additional 5,425 shares during the period. Bailard Inc. bought a new stake in Nature’s Sunshine Products in the second quarter valued at approximately $197,000. Skylands Capital LLC raised its stake in Nature’s Sunshine Products by 722.1% in the second quarter. Skylands Capital LLC now owns 333,101 shares of the company’s stock valued at $5,020,000 after buying an additional 292,581 shares during the period. Panagora Asset Management Inc. lifted its position in shares of Nature’s Sunshine Products by 8.3% in the second quarter. Panagora Asset Management Inc. now owns 70,338 shares of the company’s stock valued at $1,060,000 after buying an additional 5,392 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Nature’s Sunshine Products by 25.7% during the 2nd quarter. American Century Companies Inc. now owns 260,479 shares of the company’s stock worth $3,925,000 after acquiring an additional 53,221 shares during the period. Institutional investors and hedge funds own 79.40% of the company’s stock.

Nature’s Sunshine Products Trading Up 1.0 %

NASDAQ:NATR opened at $15.13 on Friday. The stock has a 50 day simple moving average of $14.85 and a 200 day simple moving average of $14.56. The stock has a market cap of $279.54 million, a P/E ratio of 17.19 and a beta of 0.93. Nature’s Sunshine Products, Inc. has a 1-year low of $10.81 and a 1-year high of $21.72.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on NATR shares. Canaccord Genuity Group assumed coverage on Nature’s Sunshine Products in a research note on Friday, September 13th. They issued a “buy” rating and a $18.00 price target on the stock. Canaccord Genuity Group assumed coverage on shares of Nature’s Sunshine Products in a research report on Friday, September 13th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, StockNews.com raised shares of Nature’s Sunshine Products from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th.

Insiders Place Their Bets

In other Nature’s Sunshine Products news, major shareholder Fosun Pharmaceutical Shanghai sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $13.39, for a total transaction of $40,170.00. Following the transaction, the insider now owns 69,347 shares in the company, valued at $928,556.33. This represents a 4.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 7,499 shares of company stock worth $99,802 in the last 90 days. Company insiders own 4.70% of the company’s stock.

Nature’s Sunshine Products Company Profile

Nature’s Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.